127 related articles for article (PubMed ID: 15883179)
1. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes.
Gil-Lamaignere C; Hess R; Salvenmoser S; Heyn K; Kappe R; Müller FM
J Antimicrob Chemother; 2005 Jun; 55(6):1016-9. PubMed ID: 15883179
[TBL] [Abstract][Full Text] [Related]
2. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method.
Singh J; Rimek D; Kappe R
Mycoses; 2005 Jul; 48(4):246-50. PubMed ID: 15982206
[TBL] [Abstract][Full Text] [Related]
4. Cunninghamella bertholletiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp.
Simitsopoulou M; Georgiadou E; Walsh TJ; Roilides E
Med Mycol; 2010 Aug; 48(5):720-4. PubMed ID: 20100138
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
Perkhofer S; Locher M; Cuenca-Estrella M; Rüchel R; Würzner R; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2008 Jul; 52(7):2636-8. PubMed ID: 18458135
[TBL] [Abstract][Full Text] [Related]
6. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.
Simitsopoulou M; Roilides E; Maloukou A; Gil-Lamaignere C; Walsh TJ
Mycoses; 2008 Mar; 51(2):147-54. PubMed ID: 18254752
[TBL] [Abstract][Full Text] [Related]
7. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of antifungals against Zygomycetes.
Alastruey-Izquierdo A; Castelli MV; Cuesta I; Zaragoza O; Monzón A; Mellado E; Rodríguez-Tudela JL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():71-6. PubMed ID: 19754762
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.
Cuenca-Estrella M; Gomez-Lopez A; Buitrago MJ; Mellado E; Garcia-Effron G; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Jun; 50(6):2248-50. PubMed ID: 16723597
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
Almyroudis NG; Sutton DA; Fothergill AW; Rinaldi MG; Kusne S
Antimicrob Agents Chemother; 2007 Jul; 51(7):2587-90. PubMed ID: 17452481
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
[TBL] [Abstract][Full Text] [Related]
12. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
[TBL] [Abstract][Full Text] [Related]
13. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
14. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates.
Shuford JA; Piper KE; Steckelberg JM; Patel R
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):277-81. PubMed ID: 17141454
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
Spreghini E; Orlando F; Giannini D; Barchiesi F
J Antimicrob Chemother; 2010 Oct; 65(10):2158-63. PubMed ID: 20667887
[TBL] [Abstract][Full Text] [Related]
16. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
[TBL] [Abstract][Full Text] [Related]
17. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.
Perea S; Gonzalez G; Fothergill AW; Kirkpatrick WR; Rinaldi MG; Patterson TF
Antimicrob Agents Chemother; 2002 Sep; 46(9):3039-41. PubMed ID: 12183266
[TBL] [Abstract][Full Text] [Related]
18. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.
Lamaris GA; Ben-Ami R; Lewis RE; Chamilos G; Samonis G; Kontoyiannis DP
J Infect Dis; 2009 May; 199(9):1399-406. PubMed ID: 19358672
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of fluconazole, voriconazole and caspofungin against clinical yeast isolates.
Maida CM; Milici ME; Oliveri S
J Chemother; 2007 Jun; 19(3):277-82. PubMed ID: 17594922
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of caspofungin and voriconazole against uncommon Candida spp.
Enache-Angoulvant A; Girard A; Poirot JL; Hennequin C
Int J Antimicrob Agents; 2009 Jun; 33(6):595-6. PubMed ID: 19162450
[No Abstract] [Full Text] [Related]
[Next] [New Search]
